Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
Hosted on MSN1d
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...
FiercePharma4d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Biogen Wants to Buy Its Partner Sage for Almost No Premium
Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus Target Price from Analysts
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...
BioPharma Dive4d
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
SchaeffersResearch.com4d
Sage Therapeutics Stock Headed for Best Day in 5 Years
Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...
Yahoo Finance1d
Sage Therapeutics, Inc. (SAGE)
Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share.
pharmaphorum4d
Biogen offers to buy out wilting Sage for $442 million
The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...
bovnews1d
SAGE Stock Fluctuations: The Real Story
RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James ...
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...